These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9815603)

  • 1. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
    Rodriguez CO; Legha JK; Estey E; Keating MJ; Gandhi V
    Clin Cancer Res; 1997 Nov; 3(11):2107-13. PubMed ID: 9815603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
    Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
    Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
    Aguayo A; Cortes JE; Kantarjian HM; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating MJ
    Cancer; 1999 Jan; 85(1):58-64. PubMed ID: 9921974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.
    Lambe CU; Averett DR; Paff MT; Reardon JE; Wilson JG; Krenitsky TA
    Cancer Res; 1995 Aug; 55(15):3352-6. PubMed ID: 7614470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.
    Rodriguez CO; Gandhi V
    Cancer Res; 1999 Oct; 59(19):4937-43. PubMed ID: 10519407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
    Verhoef V; Fridland A
    Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.
    Rodriguez CO; Mitchell BS; Ayres M; Eriksson S; Gandhi V
    Cancer Res; 2002 Jun; 62(11):3100-5. PubMed ID: 12036920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of nelarabine in indolent leukemias.
    Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
    J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
    Kisor DF
    Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.
    Shewach DS; Daddona PE; Ashcraft E; Mitchell BS
    Cancer Res; 1985 Mar; 45(3):1008-14. PubMed ID: 3971358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Res; 1988 Jan; 48(2):329-34. PubMed ID: 3335008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Plunkett W; Dixon DO
    Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
    Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
    Gandhi V; Plunkett W; Rodriguez CO; Nowak BJ; Du M; Ayres M; Kisor DF; Mitchell BS; Kurtzberg J; Keating MJ
    J Clin Oncol; 1998 Nov; 16(11):3607-15. PubMed ID: 9817282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.